China IND Requirements Overly Burdensome To Industry - Shanghai R&D Summit
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The pharmaceutical industry should lobby the Chinese government to relax requirements for IND approvals that discourage multinational companies from sponsoring clinical trials in China, according to Hutchison MediPharma Managing Director Samantha Du
You may also be interested in...
Generics History Hobbles Trial Work In China
NEW YORK - Fast, unpredictable change in fragmented China - where companies face retention and regulatory challenges despite in many cases being revenue-generating - brings risk as well as possibility
Generics History Hobbles Trial Work In China
NEW YORK - Fast, unpredictable change in fragmented China - where companies face retention and regulatory challenges despite in many cases being revenue-generating - brings risk as well as possibility
Merck KGaA Looks To Chinese Medicine For Oncology Candidates
Collaboration with China’s Chi-Med is part of an initiative to strengthen Merck’s natural compound expertise, exec tells “The Pink Sheet” DAILY.